



ISTH.ORG

International Society on  
Thrombosis and Haemostasis

**2026-2028**

# Public affairs agenda: Advancing global policy in thrombosis and hemostasis

The International Society on Thrombosis and Haemostasis (ISTH) is the leading global organization dedicated to thrombosis and hemostasis, advancing policy, awareness and equitable care for bleeding and clotting conditions worldwide.

## PRESENTED BY:

### ISTH Global Public Affairs Committee

Flora Peyvandi, M.D., Ph.D.  
Donna DiMichele, M.D.

## ISTH CONTACT

Louise St. Germain  
[Louise\\_StGermain@ISTH.org](mailto:Louise_StGermain@ISTH.org)



# ABOUT THE ISTH

The ISTH is the leading global organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombosis and hemostasis-related conditions. With members in more than 120 countries, the ISTH fosters collaboration among scientists, clinicians, researchers, policymakers and advocates to improve health outcomes worldwide.



## ISTH GLOBAL PUBLIC AFFAIRS AGENDA

The ISTH Global Public Affairs Agenda defines how the Society engages in global health policy, advances evidence-based decision-making and raises awareness of priority issues in thrombosis and hemostasis.

Through this agenda, the ISTH:

- Shares scientific evidence and policy insights with policymakers, regulators and global stakeholders
- Builds strategic partnerships with health organizations and government institutions
- Promotes equitable access to prevention, diagnosis and care for people affected by bleeding and clotting disorders worldwide

The ISTH's public affairs work is grounded in evidence-informed policy engagement and cross-sector collaboration. Depending on the issue and context, the Society may lead initiatives or support broader global alliances to advance shared health priorities and strengthen collective impact.

## ISTH CORE ADVOCACY THEMES

- Evidence-based guidelines and best practices
- Access to innovation and advanced therapies
- Health system strengthening and equitable access to care
- Patient partnership in policy and research
- Global alignment of clinical standards
- Digital health, artificial intelligence and data for decision-making



# CONNECTING ISTH PRIORITIES TO GLOBAL HEALTH POLICY

Aligning the ISTH's priorities with the global health policy landscape, this agenda articulates a strategic vision to transform scientific insight and community need into actionable policy, ensuring thrombosis and hemostasis are embedded in broader health frameworks to advance access, equity and innovation worldwide.

While all priority areas remain important to the ISTH's mission, the ISTH will focus intensive advocacy efforts on women's health and maternal-fetal medicine during 2025-2026, leveraging early successes to advance the broader agenda in subsequent years.

## PRIMARY FOCUS: Women's health and maternal-fetal medicine

Thrombotic and bleeding disorders uniquely impact women across their reproductive lifespan and represent a leading cause of preventable maternal complications worldwide. This area offers significant opportunity for policy impact, as it addresses recognized global health priorities while leveraging ISTH's distinctive scientific expertise.

### The ISTH will:



- Advocate for increased investment in research on pregnancy-related thrombosis, postpartum hemorrhage and bleeding disorders affecting women throughout their lives
- Promote equitable access to essential therapies including hemostatic agents, anticoagulants and advanced treatments for women globally
- Support development and uptake of standardized risk assessment tools and evidence-based clinical protocols
- Address global disparities in care quality by supporting capacity-building initiatives and provider training programs
- Champion inclusion of women's bleeding and clotting disorders in national health policies and universal health coverage frameworks
- Encourage awareness campaigns focused on early detection, prevention and elimination of preventable complications

This priority area creates opportunities to influence broader health system strengthening while establishing the ISTH as a key voice in global women's health policy discussions.



# ADDITIONAL STRATEGIC POLICY PRIORITIES

In addition to its flagship focus on women's bleeding and clotting health, the ISTH advances complementary global policy priorities to strengthen health systems, expand equitable access to care and improve outcomes across the full spectrum of thrombosis and hemostasis.

## Strengthening access to essential hematology therapies

Millions of people living with bleeding and clotting disorders rely on safe and effective therapies. The ISTH advocates to:

- Expand equitable access to plasma-derived, recombinant and non-factor therapies
- Promote global regulatory alignment for advanced hematology treatments
- Address affordability, supply and sustainability challenges
- Encourage safe, ethical and science-driven innovation

Where appropriate, the ISTH collaborates with partner organizations to amplify impact and avoid duplication of efforts.

## Integrating thrombosis and hemostasis into global NCD strategies

Thrombotic and bleeding disorders are closely linked to major noncommunicable diseases (NCDs), including cardiovascular disease, cancer and diabetes, yet remain underrepresented in global NCD frameworks. The ISTH works to:

- Advocate for inclusion in NCD policies and universal health coverage (UHC) planning
- Elevate recognition at international policy forums, including United Nations high-level meetings
- Strengthen research and data on links between coagulation, inflammation and metabolic disease
- Promote risk stratification tools within integrated NCD care models

## Innovation, regulation and equitable access

Rapid scientific advancement requires responsive and harmonized policy approaches. The ISTH supports:

- Science-based, globally aligned regulatory pathways
- Dialogue on cost-effectiveness, pricing and reimbursement challenges
- International collaboration in regulatory science and safety monitoring

## Patient safety and universal health coverage

The ISTH partners with global institutions, including the World Health Organization, to strengthen patient safety and quality of care. The Society advocates to:

- Reduce hospital-acquired venous thromboembolism (VTE) through improved prevention strategies
- Ensure diagnostics and treatments for bleeding and clotting disorders are included in essential health service packages
- Integrate thrombosis and hemostasis care into broader UHC efforts



# JOIN OUR SHARED MISSION

The ISTH Global Public Affairs Agenda reflects the shared vision, expertise and dedication of our global community including members, volunteers, partners and collaborators who contribute to the advancement of thrombosis and hemostasis worldwide. We thank you for your ongoing commitment to science, innovation and equity in health.

As we work to shape policy, strengthen health systems and improve outcomes for patients everywhere, we invite you to engage with this agenda. Whether through research, advocacy, education or collaboration, your voice and your efforts are essential in driving meaningful change.

## WITH YOUR SUPPORT

Together, we can ensure that thrombosis and hemostasis remain central to the global health conversation.

## KEEP IN TOUCH



[www.isth.org](http://www.isth.org)



[Louise\\_StGermain@ISTH.org](mailto:Louise_StGermain@ISTH.org)

